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tubulointerstitial scarring and creatinine clearance at fourInterleukin-4 ameliorates crescentic glomerulonephritis in
weeks. If treatment was delayed until inflammation was estab-Wistar Kyoto rats.
lished, there was still a reduction of injury, but without anBackground. Activated macrophages play a central role in
alteration of macrophage numbers, suggesting that IL-4 maycrescentic glomerulonephritis. Interleukin-4 (IL-4) down-regu-
be acting, in part, to reduce macrophage activation.lates many macrophage proinflammatory activities. We there-
fore studied the effect of IL-4 on glomerular injury in a model
of crescentic glomerulonephritis in the Wistar Kyoto rat.
Methods. Glomerulonephritis was induced by i.v. adminis- Crescentic glomerulonephritis is an important causetration of rabbit antirat glomerular basement membrane anti-
of end-stage renal failure. An understanding of its patho-serum (nephrotoxic serum, NTS). In experiment 1, IL-4 was
genesis is still incomplete, and current treatment is non-given from two hours before NTS until day 6. In experiment
2, rats were treated from day 0 to 7 and were then monitored specific and has a high risk of adverse effects. Experimen-
until killed on day 28. In experiment 3, IL-4 was given from tal models of crescentic nephritis in rats and rabbits have
day 4 to 7. provided considerable insight into the mechanisms byResults. Continuous IL-4 treatment (experiment 1) signifi-
which crescents form [1]. Crescent formation resultscantly (P 5 0.001) reduced proteinuria (3 6 1 mg per 24 hr
from severe damage to the glomerular capillary wall withvs. 56 6 7), fibrinoid necrosis (0.06 6 0.04 quadrants/glomulus
vs. 1.2 6 0.1), macrophage infiltration (6.7 6 2.6 cells/glom vs. disruption of the basement membrane. Macrophages
33 6 2.5), CD81 cells (1.5 6 0.6 cells/glom vs. 6.2 6 1.1), play a critical role in causing this damage [2], in part by
inducible nitric oxide synthase positive cells (0.04 6 0.04 cells/ the release of proteolytic enzymes. Once the integrityglom vs. 3.7 6 0.6), proliferating cell nuclear antigen positive
of the basement membrane is disrupted, large plasmacells (3.2 6 1 cells/glom vs. 15 6 2.3), and glomerular intercellu-
proteins (including fibrinogen) and leukocytes pass intolar adhesion molecule-1 expression. Follow-up after seven days
of treatment (experiment 2) showed that at four weeks, creati- Bowman’s space, and the clotting system becomes acti-
nine clearance was higher in treated rats (1.1 6 0.1 ml/min vs. vated, allowing the deposition of fibrin. Activation of
0.4 6 01, P 5 0.011), and both glomerular scarring (P 5 0.006) the coagulation pathway is predominantly due to tissueand tubular atrophy (P 5 0.006) were less. Delayed treatment
factor [3], and activated macrophages are a major source(experiment 3) reduced proteinuria (41 6 5 mg per 24 hr vs.
of this activity [4, 5]. There is then accumulation of cells97 6 9, P 5 0.004) and fibrinoid necrosis (0.39 6 0.05 quadrants/
glom vs. 1.6 6 0.1, P 5 0.004). There was no difference in within Bowman’s space because of further recruitment
macrophage infiltration, but inducible nitric oxide synthase of monocytes/macrophages and proliferation of macro-
positive cells were reduced (0.6 6 0.1 cells/glom vs. 1.8 6 0.4, phages and glomerular epithelial cells.P 5 0.01) as were ED31 cells (0.18 6 0.06 cells/glom vs. 1.86 6
When monocytes arrive in the inflamed glomerulus,0.21, P 5 0.004).
they rapidly become activated and develop a proinflam-Conclusion. In this model of crescentic glomerulonephritis,
early IL-4 treatment abolished proteinuria and markedly re- matory phenotype. This has been shown by both func-
duced glomerular inflammation. If treatment was stopped after tional studies, which demonstrate increased secretion of
seven days, there was continuing benefit on glomerular and reactive oxygen species [6, 7], tissue factor [5], an altered
pattern of eicosanoid synthesis [7], and by immunohisto-
chemical studies showing increased expression of classKey words: macrophage activation, inflammation, glomerular injury,
proteinuria, tubulointerstitial scarring. II histocompatibility antigens [7], inducible nitric oxide
synthase (iNOS) [8], and sialoadhesin [9]. A major stimu-Received for publication July 31, 1998
lus to macrophage activation is likely to be the intraglo-and in revised form November 2, 1998
Accepted for publication November 3, 1998 merular release of proinflammatory cytokines such as
interleukin (IL)-1b and tumor necrosis factor (TNF) [10]. 1999 by the International Society of Nephrology
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Thus, cytokines that reduce macrophage activation access to food and water. Rats were killed under isoflu-
rane anesthesia, and blood was collected from the abdomi-would be predicted to reduce glomerular damage in the
acute phase of crescentic glomerulonephritis, and there- nal aorta. Samples of kidney, liver, lung, and spleen were
placed in 10% formal saline, and samples of kidney werefore, we have examined the effect of IL-4.
Interleukin-4 is a 20 kDa immunoregulatory cytokine snap frozen in optimal cutting temperature (OCT) com-
pound using isopentane cooled in liquid nitrogen. Uri-that is secreted by T cells, mast cells, basophils, and a
subset of natural killer cells [11]. It is produced by T nary protein was measured by the sulfosalicylic acid
method [23]. Urinary and serum creatinine concentrationshelper 2 (Th2) CD41 T cells and facilitates the develop-
ment of a Th2 phenotype. In vitro, it inhibits interferon were measured by the Jaffe method on an autoanalyzer.
(IFN)-g production by activated T cells [12]. IL-4 inhibits
Experimental designmany functions of activated macrophages, including the
secretion of reactive oxygen intermediates [13] and nitric Three separate experiments were performed.
Experiment 1. Rats were treated with intraperitonealoxide [14], and the expression of tissue factor [15] and
macrophage colony stimulating factor [16]. It suppresses (i.p.) IL-4 0.25 ml (N 5 8) or 0.5 ml (N 5 8) twice
daily for six days. Control rats were given i.p. controlmacrophage TNF-a and IL-1b [17] production and up-
regulates expression of IL-1 receptor antagonist [18]. It supernatant 0.5 ml twice daily (N 5 8). The first injec-
tions were given two hours before induction of nephritis.stimulates macrophage 15-lipoxygenase activity, which
may reduce synthesis of the proinflammatory leuko- Rats were placed in metabolic cages from day 5 to day
6 and were killed on day 6.triene B4 [19]. IL-4 also decreases monocyte expression
of all three classes of Fc receptor for IgG [20]. Experiment 2. Rats were treated with 0.5 ml IL-4 i.p.
twice daily (N 5 6) or 0.5 ml control supernatant (N 5 6).We have recently shown that IL-4 ameliorated glomer-
ular injury in a model of accelerated nephrotoxic nephri- The first injections were given two hours before induc-
tion of nephritis, and treatment was continued for seventis in Sprague-Dawley rats when given for four days
starting before the injection of nephrotoxic serum [21]. days. The rats were then followed with weekly 24-hour
urinary collections until four weeks, when they were killed.We have now examined the effect of IL-4 on a model of
more severe crescentic glomerulonephritis in the Wistar Experiment 3. Rats were given 0.5 ml IL-4 i.p. twice
daily (N 5 6) or control supernatant (N 5 6) startingKyoto (WKY) rat. We have studied the effect of (a)
continuous treatment given for six days, beginning just on the fourth day after the induction of nephritis. Rats
were placed in metabolic cages from day 6 to day 7 andbefore induction of nephritis; (b) the long-term effect of
a short course of IL-4; and (c) the effect of delaying IL-4 were killed on day 7.
treatment until the fourth day, by which time there is a
Histology and immunohistochemistrymarked glomerular macrophage infiltrate.
In experiments 1 and 3, glomerular fibrinoid necrosis
was assessed in hematoxylin and eosin (HE)-stained sec-
METHODS
tions and was quantitated by scoring the number of quad-
Reagents rants of each glomerulus involved. At least 25 glomeruli
were counted, and a mean score of quadrants/glomerulusNephrotoxic serum (NTS), a rabbit antiserum to rat
glomerular basement membrane, was prepared as de- was calculated. In experiment 2, glomerular scarring and
tubular damage were assessed in HE-stained sections.scribed previously [22]. Recombinant rat IL-4 was pro-
duced as cell culture supernatant from a Chinese hamster Glomerular scarring was assessed by counting the per-
centage of glomeruli containing fibrous or fibrocellularovary (CHO)-K1 cell line transfected with rat IL-4 cDNA
(a gift from Dr. D. Fowell, MRC Immunology Unit, Ox- crescents. Tubular damage was assessed semiquantita-
tively by estimating the percentage of tubules showingford, UK). The concentration of IL-4 was measured by
enzyme-linked immunosorbent assay using the Biosource atrophy or dedifferentiation and converting this to a
score from 0 to 4. Apoptotic cells were counted in HE-rat IL-4 Immunoassay Kit (Lifescreen, Watford, UK). Two
batches of supernatant were used in these experiments. stained sections. A cell was considered apoptotic when
it showed chromatin condensation along the nuclearThe first batch, used in experiment 1, contained 5.1 mg/
ml IL-4, and the second batch, used in experiments 2 membrane with intensely basophilic staining and/or nu-
clear fragmentation into spherical structures containingand 3, contained 9.6 mg/ml IL-4. Control rats received cell
culture supernatant from the parent CHO-K1 cell line. condensed chromatin [24]. All analyses were carried out
on randomized sections.
Nephrotoxic nephritis Frozen sections were stained by direct immunofluo-
rescence for rabbit immunoglobulin using fluoresceinMale WKY rats weighing 200 to 220 g were given 0.1
ml of NTS intravenously. Urine was collected by housing isothiocyanate (FITC)-conjugated swine antirabbit im-
munoglobulin (Nordic Immunology, Tilburg, The Neth-the rats in metabolic cages for 24-hour periods, with free
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erlands), for rat immunoglobulin using FITC-conjugated
rabbit antirat immunoglobulin (Dako, Cambridge, UK),
and for fibrinogen using FITC-conjugated goat antirat
fibrinogen (ICN, Thame, UK). Intercellular adhesion
molecule-1 (ICAM-1) expression was detected in frozen
sections by staining with mouse antirat ICAM-1 (R&D
Systems, Abingdon, UK) followed by FITC-conjugated
rabbit antimouse immunoglobulin (Dako). Paraffin sec-
tions were used for immunohistochemistry for macro-
phages (mAb ED1; Serotec, Oxford, UK), macrophage
sialoadhesin (mAb ED3; Serotec), inducible nitric oxide
synthase (iNOS; mouse anti-iNOS mAb; Affiniti, Exeter,
UK), and proliferating cell nuclear antigen (PCNA, mAb
PC10; Dako). The primary antibodies were used at the
following concentrations: ED1, 1:500; ED3, 1:200; iNOS,
1:100; and PCNA,1:50. ED1 was detected with an indi-
rect peroxidase technique using peroxidase-labeled rab-
bit antimouse immunoglobulin (Dako), and ED3 and
iNOS were detected using biotinylated rabbit antimouse
antibody (Dako) and streptavidin-biotin-peroxidase com-
plexes (Dako). CD8-positive cells were identified in fro-
zen sections by staining with mAb MRC OX8 (Serotec)
using the streptavidin-biotin-peroxidase technique. Cells
were counted in randomized sections. Where possible,
at least 25 glomeruli were counted per section.
For quantitation of fluorescent staining, images were
captured using a color CoolView camera (Photonic Sci-
ence, Robertsbridge, UK) and were analyzed using Image-
Pro plus software (Media Cybernetics, Silver Spring, MA,
USA). Images were converted to gray scale, and the aver-
age pixel intensity of individual glomeruli was recorded. Fig. 1. Renal histology six days after the induction of nephritis in
experiment 1. (A) Control. Most of the glomeruli show prominentResults are shown as arbitrary units of intensity.
segmental fibrinoid necrosis. (B) Interleukin-4 (IL-4) treated (0.5 ml
b.i.d.). The glomeruli show slight hypercellularity but no fibrinoid necro-Statistics sis [hematoxylin and eosin (HE) stain, 3150].
Results are presented as mean 6 se. Comparisons
between treatments were by Mann–Whitney U-test.
Experiment 2
RESULTS
One rat in the IL-4–treated group died at 12 days. As
Experiment 1 in experiment 1, there was abolition of proteinuria at
one week in the IL-4–treated animals (Fig. 4). However,All rats survived until the end of the experiment. The
rats treated with control supernatant developed protein- by week 4, the level of proteinuria was the same in the
two groups. In the IL-4–treated group, the creatinineuria with prominent glomerular fibrinoid necrosis and
glomerular macrophage infiltration (Figs. 1 and 2). Treat- clearance at four weeks (1.1 6 0.1 ml/min) did not differ
from that of normal rats, whereas in the control group,ment with either dose of IL-4 (0.25 ml or 0.5 ml) com-
pletely abolished proteinuria (Table 1). Macrophage in- it was significantly reduced (0.4 6 0.1/min; U 5 1, P 5
0.011). Macroscopically, the kidneys of the IL-4–treatedfiltration, fibrinoid necrosis, CD81 cells, iNOS-positive
glomerular cells, and glomerular PCNA staining were rats appeared normal, whereas those of the control rats
showed prominent fine granularity of the surface. Thereall significantly reduced by IL-4 in a dose-dependent
manner (Figs. 1 and 2; Table 1). Glomerular ICAM-1 was a significant reduction in the percentage of glomeruli
showing fibrous or fibrocellular crescents (control, 93 6staining was significantly reduced by the higher dose of
IL-4. After seven days of treatment, the rats treated with 2%; IL-4 treated, 41 6 14%; U 5 0, P 5 0.006) and in
the score for tubular damage (control, 3.7 6 0.2; IL-4IL-4 showed small amounts of ascites. Histology of the
liver showed drop out of hepatocytes in acinar zone 3 treated, 1.0 6 0.3; U 5 0, P 5 0.006; Fig. 5). The numbers
of glomerular macrophages were increased in the IL-4–with hepatocyte apoptosis (Fig. 3A).
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Fig. 2. Macrophage infiltration demonstrated by immunohistochemis- Fig. 3. (A) Liver histology from a rat from experiment 1 treated with
try with monoclonal antibody ED1 in experiment 1, six days after IL-4 (0.5 ml b.i.d.). There is prominent hepatocyte loss around a central
induction of nephritis. (A) Control. Many ED11 macrophages are vein with crowding of the remaining Kupffer cells. (HE 3300). (B)
present in the glomerular tuft. (B) IL-4 treated (0.5 ml b.i.d.). Glomeru- Liver histology from a rat from experiment 2 treated with IL-4 for one
lar macrophage infiltration is markedly reduced compared with control week and then killed at four weeks. There is mild bridging fibrosis
(immunoperoxidase with hematoxylin counterstain 3300). extending from this central vein (HE 3300).
Table 1. Effect of interleukin-4 (IL-4) given twice daily from the time of induction of glomerulonephritis until day 6
Proteinuria Fibrinoid necrosis Macrophages/ CD81 iNOS1 PCNA1 ICAM-1
N mg/24 hr quadrants/glom glom cells/glom cells/glom cells/glom staining
Control 8 69 6 6 1.3 6 0.1 32 6 1.2 6.2 6 1.1 3.0 6 0.4 15 6 2.3 100 6 6.2
IL-4 0.25 ml bid 8 4 6 2a 0.21 6 0.1a 12.6 6 2.3a 3.1 6 1.0b 0.9 6 0.3a 5.4 6 0.5a 84 6 5.9
IL-4 0.5 ml bid 8 1 6 1a 0.04 6 0.02a 4.8 6 1.3a 1.5 6 0.6a 0.05 6 0.03a 3.2 6 1.0a 75 6 7.9b
Abbreviations are: glom, glomerulus; iNOS, inducible nitric oxide synthase; PCNA, proliferating cell nuclear antigen; ICAM, intercellular adhesion molecule.
aP 5 0.001 compared with control
bP 5 0.025 compared with control
treated rats (36 6 5 macrophages/glom) compared with was seen. The livers of the IL-4–treated rats showed
brisk mitotic activity in hepatocytes, with some mild focalcontrols (23 6 2 macrophages), but this did not reach
statistical significance (U 5 5, P 5 0.068). The numbers bridging fibrosis between portal veins (Fig. 3B).
of CD81 cells were not significantly different (control,
Experiment 30.32 6 0.09 cells/glom; IL-4 treated, 0.66 6 0.38). There
was no difference in glomerular deposition of rat immu- When IL-4 treatment was delayed until the fourth day,
there was still a significant reduction in proteinuria bynoglobulin between the two groups (control, 21.3 6 3.0
intensity units/glom; IL-4 treated, 20.5 6 4.0). No ascites day 7, although not as marked as that seen with continu-
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established glomerular fibrinoid necrosis by six days,
makes it unlikely that an acquired immune response to
the planted rabbit immunoglobulin plays an important
part in pathogenesis. This is supported by our previous
observations: First, deposition of rat immunoglobulin
was not seen in the glomeruli until day 6. Second, fluo-
rescence-activated cell sorter analysis of single-cell prep-
arations from glomeruli did not show any evidence of
glomerular T-cell infiltration, as assessed by expression
of CD3, T-cell receptor ab, or T-cell receptor gd, until
day 11. We therefore believe that this model allows us
to study the effect of IL-4 on the effector phase of glo-
merular inflammation rather than on the generation of
the immune response.
Our first experiment, in which IL-4 was started imme-
diately before the induction of nephritis, showed a dra-
matic reduction in injury. By six days, a time at which
fibrinoid necrosis is maximal in the model, there was a
complete abolition of proteinuria with either dose of
IL-4 tested. With the lower dose, there was an 84%
reduction in fibrinoid necrosis, and with the higher dose
Fig. 4. Graph of proteinuria in experiment 2. Closed symbols denote there was a 97% reduction. This was accompanied by a
IL-4 treated rats and open symbols are control nephritic rats. *P 5 reduction in glomerular macrophages of 41% with the0.006.
lower dose and 85% with the higher dose. This suggests
that, although the major reason for the amelioration of
injury is probably the reduction of macrophage influx,
there may also be another effect on injury once theous treatment (Table 2). Glomerular injury, as assessed
macrophages have entered the glomerulus. Previousby fibrinoid necrosis, was significantly reduced in the
studies have shown that the mechanism of macrophagetreated group (Table 2). There was no difference in num-
infiltration involves the interaction of ICAM-1 with lym-bers of glomerular macrophages, but the numbers of
phocyte function associated antigen-1 (CD11a/CD18).iNOS-positive cells and ED3-positive cells were signifi-
Thus, there is up-regulated expression of ICAM-1cantly reduced. CD81 cells were reduced, but this did
mRNA by one hour [26] and of immunohistochemicallynot reach statistical significance. There was no difference
detectable ICAM-1 by one day [27], and injection of anti-in cells staining for PCNA or in numbers of apoptotic
bodies against ICAM-1 and CD11a reduced proteinuria,cells (Table 2). Glomerular deposition of rabbit immuno-
macrophage influx, and crescent formation [27]. Mono-globulin did not differ between the groups.
cyte chemoattractant protein-1 has also been shown to
play a role in the early macrophage influx in this model
DISCUSSION [28]. Our results show that IL-4 treatment reduces glo-
In order to examine the effect of IL-4 in crescentic merular ICAM-1 expression. Potential mediators of the
nephritis, we have chosen the model of nephrotoxic ne- increase in ICAM-1 expression are IL-1b and TNF-a,
phritis in the WKY rat first described by Kawasaki et al which have been shown to increase ICAM-1 expression
[25]. This is a reproducible model with rapid develop- rapidly in endothelial cells [29] and which are up-regu-
ment of glomerulonephritis following a single injection lated early in the course of this model [26]. IL-4 is known
of nephrotoxic serum. Our previous characterization of to suppress macrophage TNF-a and IL-1b [17], and we
this model (Tam et al, manuscript submitted for publica- therefore hypothesize that the action of IL-4 in reducing
tion) showed that there is a rapid influx of macrophages ICAM-1 is via reduced TNF-a and IL-1b synthesis. Our
that plateaus at day four. Proteinuria is first seen at day current studies are addressing these mechanisms.
3 to 4, and histology on day 4 shows segmental fibrinoid We have recently studied the effect of IL-4 in acceler-
necrosis in glomeruli that becomes more severe by day ated nephrotoxic nephritis in the Sprague-Dawley rat
6, leading to the development of cellular crescents in a [21]. This differs from the WKY model used in the cur-
mean of 63% of glomeruli by day 11. By 6 weeks, rats rent study in that it depends on preimmunization with
developed renal failure (creatinine of more than 300 rabbit immunoglobulin to induce an autologous immune
mmol/liter), with a great majority of the glomeruli show- response before the injection of nephrotoxic serum. In
accelerated nephrotoxic nephritis (NTN), IL-4 treatmenting sclerosis. The very rapid onset of this model, with
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Fig. 5. Renal histology four weeks after the in-
duction of nephritis in experiment 2. (A) Con-
trol rat. The glomeruli show prominent segmen-
tal scarring and fibrous crescents. The tubules
show dedifferentiation, and there is an intersti-
tial chronic inflammatory infiltrate. (B) IL-4
treated rat. There is much better preservation
of tubular architecture with no significant in-
flammation (HE 3150).
started just before the injection of nephrotoxic serum decoy receptor) in the glomeruli of treated rats but not
control rats.(NTS) produced a 73% reduction in albuminuria and
79% reduction in thrombosis. The model showed only We wished to study whether the early reduction in
injury that we found with a short course of IL-4 wouldmodest glomerular macrophage infiltration (7.0 6 0.5
macrophages/glom) compared with the WKY model, but be maintained once the IL-4 treatment was stopped. In
experiment 2, we therefore followed the rats for a furtherthere was a small but significant reduction in macrophage
infiltration in the IL-4–treated group (5.3 6 0.4 macro- three weeks after a seven-day course of IL-4. In the un-
treated rats, there was a reduction in creatinine clearancephages/glomerulus). In that study, no difference in ex-
pression of IL-1b mRNA was found at four days; how- with marked glomerular scarring and tubular atrophy.
All of these parameters were improved in the IL-4–ever, there was expression of IL-1 receptor type II (IL-1
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Table 2. Effect of IL-4 given twice daily from day 4 to day 7 after induction of glomerulonephritis
Proteinuria Fibrinoid Macrophages/ iNOS1 PCNA1 ED31 CD81 Apoptosis
N mg/24 hr quadrants/glom glom cells/glom cells/glom cells/glom cells/glom cells/glom
Control 6 97 6 9 1.59 6 0.13 61 6 6 1.83 6 0.40 17.7 6 1.6 1.86 6 0.21 4.55 6 0.71 0.42 6 0.04
IL-4 6 41 6 5b 0.39 6 0.05b 60 6 3 0.56 6 0.10a 17.0 6 1.1 0.18 6 0.06b 2.95 6 0.27 0.40 6 0.05
Abbreviations are in Table 1.
aP 5 0.01 compared with control
bP 5 0.004 compared with control
treated animals, showing that reduction of initial injury of macrophage activation. There was no effect on the
number of proliferating cells or on apoptosis.led to a reduction in subsequent scarring. However, the
Interleukin-4 treatment has been previously tested inIL-4–treated animals had developed prominent glomer-
a mouse model of accelerated NTN. In one study [32],ular macrophage infiltration and proteinuria by this time,
C57BL/6 mice were preimmunized with sheep immuno-and it will be necessary to carry out further long-term
globulin, given sheep nephrotoxic serum at 10 days, andfollow-up to see whether this resolves without scarring.
then killed 10 days later. IL-4 treatment was givenWe considered the possibility that the rapid increase
throughout the experiment. This is a strain of mice thatin proteinuria after stopping IL-4 could be due to an
mounts a strong Th1 response, and the authors haveenhanced humoral immune response but found no differ-
previously provided evidence that glomerulonephritis inence in glomerular deposition of rat immunoglobulin.
this strain is dependent on CD41 T cells [33]. IL-4 treat-The only side-effect seen with IL-4 treatment was on
ment abolished crescent formation and significantly at-the liver. After six days of treatment, there was loss of
tenuated glomerular fibrin deposition and both T cellhepatocytes around central veins, which appeared to be
and macrophage accumulation. The authors attributeddue to hepatocyte apoptosis without significant inflam-
the improvement to an attenuation of the Th1 responsemation. The cause of this unusual change is not clear. It
by IL-4. They have also studied the same model but withwas not seen in the control rats that were given superna-
IL-4 treatment started 72 hours after the initiation oftant from nontransfected CHO-K1 cells. Transient eleva-
disease and continued until day 10 [34]. In that study,tions of liver enzymes has been reported in a trial of
IL-4 did not reduce crescent formation or protect renalIL-4 in patients with Kaposi’s sarcoma [30] and in a
function; however, the combination of IL-4 with IL-10phase I dose toxicity trial [31], but no histological changes
significantly reduced crescent formation and preservedwere described. Importantly, the liver damage we saw
renal function. The failure of delayed treatment withappeared to have almost completely resolved three
IL-4 to influence crescentic glomerulonephritis in theweeks after stopping IL-4, with increased hepatocyte
mouse, compared with the success in our rat model, may
mitosis consistent with regeneration.
be related to differences in dosage, in pathogenesis, or
The results of the first experiment suggested that the in species.
reduction in injury was relatively greater than the reduc- In the same mouse model, there is also evidence that
tion in macrophage numbers, and this was similar to endogenous IL-4 has an effect on reducing glomerular
what we had found in our previous study on accelerated inflammation. Thus, mice genetically deficient in IL-4
NTN [21]. This indicates that IL-4 may also have the showed more severe glomerulonephritis with increased
effect of reducing injury mediated by macrophages that renal impairment and crescent formation [35]. This was
are already in the glomerulus. Therefore, in order to test associated with an increased antigen-specific Th1 re-
this hypothesis and to mimic more closely the treatment sponse shown by increased skin delayed-type hypersensi-
of clinical renal disease (which presents with established tivity. It is not clear how far the influence of endogenous
glomerulonephritis), we carried out a third experiment IL-4 in this model is related to modulation of the immune
in which treatment was delayed until the fourth day. response and how far to a direct anti-inflammatory effect
By this time, proteinuria was apparent, and there was in the glomerulus.
marked glomerular hypercellularity. We found that IL-4 In summary, we have shown in a model of crescentic
treatment was still effective in reducing proteinuria and glomerulonephritis in the WKY rat that IL-4 given from
fibrinoid necrosis but that there was no effect on macro- the time of induction of glomerulonephritis is able to
phage numbers, suggesting that treatment may alter mac- abolish proteinuria and markedly reduce glomerular fi-
rophage activation to reduce macrophage-mediated in- brinoid necrosis. This is associated with a marked reduc-
jury. In keeping with this hypothesis, we found that there tion in glomerular macrophage accumulation. The bene-
was a reduction in the number of cells expressing iNOS ficial effect of seven days of treatment is still apparent
at four weeks, with preservation of renal function andand also in the expression of sialoadhesin, a marker
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lates the macrophage colony-stimulating factor receptor in murinereduced glomerular and tubulointerstitial scarring. If
macrophages. J Leukoc Biol 60:644–650, 1996
treatment is started once glomerular inflammation is es- 17. Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamil-
ton JA: Potential antiinflammatory effects of interleukin 4: Sup-tablished, there is no longer an effect on macrophage
pression of human monocyte tumor necrosis factor a, interleukininfiltration; however, there is still reduction in injury, and
1 and prostaglandin E2. Proc Natl Acad Sci USA 86:3803–3807,we have shown that this is associated with a reduction in 1989
18. Vannier E, Miller LC, Dinarello CA: Coordinated antiinflam-markers of macrophage activation.
matory effects of interleukin 4: Interleukin 4 suppresses interleukin
1 production but up-regulates gene expression and synthesis of
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